XTX Topco Ltd Has $301,000 Holdings in ResMed Inc. (NYSE:RMD)

XTX Topco Ltd decreased its position in ResMed Inc. (NYSE:RMD - Free Report) by 89.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,235 shares of the medical equipment provider's stock after selling 10,069 shares during the quarter. XTX Topco Ltd's holdings in ResMed were worth $301,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in RMD. UMB Bank n.a. raised its stake in ResMed by 1.9% during the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 47 shares during the period. Ascent Group LLC grew its holdings in shares of ResMed by 1.7% during the third quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider's stock valued at $714,000 after purchasing an additional 48 shares during the last quarter. Inspire Advisors LLC raised its position in shares of ResMed by 1.9% during the 2nd quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider's stock worth $586,000 after purchasing an additional 56 shares during the period. Concurrent Investment Advisors LLC lifted its holdings in shares of ResMed by 3.1% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider's stock worth $469,000 after purchasing an additional 57 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its position in ResMed by 2.0% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 3,043 shares of the medical equipment provider's stock valued at $743,000 after purchasing an additional 60 shares during the period. 54.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RMD. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research report on Friday, October 25th. KeyCorp boosted their price objective on ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a research report on Friday, October 25th. Stifel Nicolaus began coverage on ResMed in a report on Friday, December 13th. They issued a "hold" rating and a $250.00 price objective for the company. StockNews.com raised ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Finally, Wolfe Research reissued an "underperform" rating and issued a $180.00 price target on shares of ResMed in a research note on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $227.91.

ResMed Price Performance

NYSE RMD traded down $12.41 on Wednesday, reaching $230.21. The company's stock had a trading volume of 868,240 shares, compared to its average volume of 1,016,577. ResMed Inc. has a twelve month low of $164.12 and a twelve month high of $260.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. The firm's 50 day moving average is $243.05 and its two-hundred day moving average is $228.22. The stock has a market cap of $33.79 billion, a PE ratio of 30.49, a PEG ratio of 1.73 and a beta of 0.68.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.64 EPS. As a group, sell-side analysts predict that ResMed Inc. will post 9.34 EPS for the current year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Thursday, November 7th were given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Thursday, November 7th. ResMed's payout ratio is presently 28.08%.

Insider Buying and Selling at ResMed

In other ResMed news, insider Kaushik Ghoshal sold 4,260 shares of the business's stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $238.48, for a total value of $1,015,924.80. Following the transaction, the insider now owns 21,788 shares in the company, valued at $5,196,002.24. The trade was a 16.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $231.91, for a total value of $3,405,134.53. Following the sale, the chief executive officer now owns 464,169 shares of the company's stock, valued at approximately $107,645,432.79. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,725 shares of company stock worth $11,253,448. 0.71% of the stock is currently owned by company insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.